1. Home
  2. |Professionals
  3. |Eline D'Joos

Eline D'Joos

Associate | She/Her/Hers
Associate | She/Her/Hers
ZWRqb29zQGNyb3dlbGwuY29t
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Eline D’Joos is a life sciences associate in Crowell & Moring’s Brussels office. Her practice focuses on regulatory issues and commercial transactions in the life science sector, as well as interplays with general intellectual property and data protection questions. 

Eline has advised multinational companies and start-ups as well as research institutes in the pharmaceutical, biotech, and medical devices sectors on a variety of complex matters, including clinical trials, product approvals, regulatory incentives, market access, biosimilars, orphan drugs, pediatrics, and Belgian supplementary protection certificates. Digital transformation in the health sector is also one of Eline’s main focus areas.

Eline also has experience in drafting and negotiating high value IP licenses, R&D collaborations, and commercial agreements. In addition, she has assisted with mergers and acquisitions of life sciences companies as well as patent infringement proceedings and preliminary injunctions.

Career & Education

    • Catholic University of Leuven, Bachelor of law, magna cum laude (best bachelor student award), 2017
    • Catholic University of Leuven, Research master of law, magna cum laude, 2019
    • Catholic University of Leuven, Master of education, cum laude, 2020
    • Catholic University of Leuven, Bachelor of law, magna cum laude (best bachelor student award), 2017
    • Catholic University of Leuven, Research master of law, magna cum laude, 2019
    • Catholic University of Leuven, Master of education, cum laude, 2020

    • Belgium
    • Belgium

    • Dutch
    • English
    • French
    • Dutch
    • English
    • French

Eline's Insights

Client Alert | 5 min read | 04.13.26

EU Pharma Package: Global (Orphan) Marketing Authorization Compromise Proposal

In our fifth alert in this EU Pharma Package Series, we provided an analysis of the background and ongoing legal debates regarding the concept of the global marketing authorization (GMA). We discussed in particular the missed opportunities in the Pharma Package to further codify and clarify the GMA, in view of its central role in determining the regulatory data protection (RDP) rights of a medicinal product....

View All Insights

Insights

Client Alert | 5 min read | 04.13.26

EU Pharma Package: Global (Orphan) Marketing Authorization Compromise Proposal

Client Alert | 3 min read | 04.07.26

EU Pharma Package: Fiscal Imports in the Supply Chain Compromise Proposal

Client Alert | 5 min read | 03.30.26

The EU Pharma Package: The Transferable Exclusivity Voucher Compromise Proposal

Client Alert | 5 min read | 03.22.26

The EU Pharma Package: Regulatory Data Protection Compromise Proposal

View All Insights

Practices

Industries

Eline's Insights

Client Alert | 5 min read | 04.13.26

EU Pharma Package: Global (Orphan) Marketing Authorization Compromise Proposal

In our fifth alert in this EU Pharma Package Series, we provided an analysis of the background and ongoing legal debates regarding the concept of the global marketing authorization (GMA). We discussed in particular the missed opportunities in the Pharma Package to further codify and clarify the GMA, in view of its central role in determining the regulatory data protection (RDP) rights of a medicinal product....

View All Insights